Evidence map›Paper›PMID 40255066›Full record

ArticleClinical hemorheology and microcirculation2025

Effect of dalcetrapib, voxelotor and their combination on red blood cell deformability and sickling in sickle cell disease.

Claire Bordat, Elie Nader, Philippe Connes, Philippe Joly, Solene Poutrel, Anne Perez, Eric Niesor

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Clinical hemorheology and microcirculation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Retraction · 2025-11-23Compromised Peer Review · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Third Party Involvement · Investigation by Journal/Publisher ·
  • Retracted
5 · Who and what money

Authors and funding

7 authors.

Claire BordatHartis Pharma SA Nyon, Nyon, Switzerland.
Elie NaderLaboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France.
Philippe ConnesLaboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France.
Philippe JolyLaboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France.
Solene PoutrelLaboratory LIBM EA7424, Vascular Biology and Red Blood Cell Team, University of Lyon, Lyon, France.
Anne PerezHartis Pharma SA Nyon, Nyon, Switzerland.
Eric NiesorHartis Pharma SA Nyon, Nyon, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to test the effects of dalcetrapib and voxelotor on red blood cells (RBC) of sickle cell patients. Oxygen gradient ektacytometry was performed to measure RBC deformability in normoxia and hypoxia, as well as the propensity of RBC to sickle. Voxelotor and dalcetrapib reduced the propensity of RBC to sickle under deoxygenation and increased RBC deformability in hypoxia. Dalcetrapib did not affect the affinity of hemoglobin S (HbS) to oxygen. Combining the two molecules caused greater RBC rheological improvement. Our findings suggest that dalcetrapib could block HbS polymerization without affecting HbS oxygen affinity.

Indexed as

Anemia, Sickle CellErythrocyte DeformabilityErythrocytesAdultBenzaldehydesEstersFemaleHemoglobin, SickleHumansMaleOxygenPyrazinesPyrazolesBenzaldehydesEstersHemoglobin, SickleOxygenPyrazinesPyrazolesvoxelotordalcetrapibred blood cell rheologysickle cell diseasesickling

Identifiers

PMID40255066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.